SAN DIEGO, CA, USA I August 18, 2025 I Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...

Melanocortin receptor agonists offer a promising, differentiated mechanism that targets key drivers of retinal diseases, including DR.

HANGZHOU, China I August 18, 2025 I Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying ...

Filings both for the obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination submitted to EMA by our partner, Menarini, for treatment ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors ...

RESEARCH TRIANGLE PARK, NC, USA I August 18, 2025 I Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases ...

NEEDHAM, MA, USA I August 18, 2025 I Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and ...

NEWPORT BEACH, CA, USA I August 18, 2025 I jCyte, Inc. is pleased to announce the first patients have been enrolled and treated in the JC02-88 study ...

Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the ...

NEW YORK, NY, USA I August 15, 2025 I Pfizer Inc. (NYSE: PFE) today announced results from the Phase 3 THRIVE-131 study evaluating inclacumab, an ...

ROCKVILLE, MD, USA and SUZHOU, China I August 17, 2025 I Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...

SÖDERTÄLJE, Sweden I August 18, 2025 I Anocca AB (‘Anocca’ or the ‘Company’), a leading clinical-stage T-cell immunotherapy company, has successfully raised ...